Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 15/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 15/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 14/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 14/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 12/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26334441 | 1.00 | HTR2C (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2379324 | 1.00 | HTR2C (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL6367254 | 1.00 | HTR2C (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2846979 | 1.00 | HTR2C (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL6368277 | 1.00 | HTR2C (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL21816672 | 0.98 | HTR2C (0.45) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL377976 | 0.80 | CHRNB2 (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL18081172 | 0.80 | CHRNB2 (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1481267 | 0.80 | CHRNB2 (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL15956717 | 0.78 | CHRNB2 (0.45) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118302426-A | Compounds and methods for modulating splicing | 雷密克斯医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118234724-A | Compounds and methods for modulating splicing | 雷密克斯医疗公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-118076612-A | Sulfur-containing heteroaromatic tricyclic KRAS inhibitors | 医睿世康药业研发公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-114450284-B | 6, 7-Dihydro-5H-pyrido [2,3-C ] pyridazine derivatives as BCL-XL protein inhibitors | 法国施维雅药厂 | 2024-05-07 | — | — | CN | disclosed |
| CN-117642393-A | Novel PARP7 inhibitor and application thereof | 上海齐鲁制药研究中心有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-116981673-A | Novel thiadiazolopyrimidinone derivatives | 豪夫迈·罗氏有限公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-4240736-A1 | PPAR GAMMA MODULATORS AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2023-09-13 | — | — | EP | disclosed |
| CN-115677667-A | Bifunctional chimera heterocyclic compound and application thereof as androgen receptor degrading agent | 海创药业股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2022099144-A1 | ΡΡΑRγ MODULATORS AND METHODS OF USE | Eisai R&D Mangement Co., Ltd. (JP) | 2022-05-12 | — | — | WO | disclosed |